Latest news with #Aurobindo
Business Upturn
28-05-2025
- Business
- Business Upturn
Aurobindo Pharma shares fall over 2% after Citi maintains ‘Sell' rating, cuts target price to Rs 1,100
By Aman Shukla Published on May 28, 2025, 10:08 IST Aurobindo Pharma shares fell over 2% after Citi maintained a 'Sell' rating and lowered its target price to ₹1,100. Citi expressed concerns about flattening growth in the US market and rising margin pressures ahead. As of 10:06 AM, the shares were trading 2.12% lower at Rs 1,165.90. In Q4FY25, Aurobindo reported a 10.6% year-on-year revenue increase to ₹8,382 crore, but net profit slightly dipped 0.5% to ₹902.8 crore. Citi highlighted that the company's adjusted EBITDA was around 5% below expectations. Excluding the $40–60 million contribution from gRevlimid, the baseline EBITDA margin stood at 18.5%, down 100 basis points compared to last year, despite a one-time ₹1,000 crore cost benefit. Management's outlook was described as underwhelming, projecting only high single-digit revenue growth and no significant improvement in injectables for FY26. Citi pointed out that although the US business saw 10% volume growth in FY25, signs of flattening sales and the removal of gRevlimid from the product mix may pressure margins over the next few quarters. Due to these factors, Citi cut its FY26–27 earnings per share estimates by 8%, indicating cautious sentiment around Aurobindo's near-term prospects. Investors should watch the company's US market performance closely as margin risks remain a key concern. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
27-05-2025
- Business
- Time of India
Aurobindo Pharma shares in focus after Q4 profit dips marginally to Rs 903 cr
Aurobindo Pharma shares are likely to be in focus on Tuesday after the Hyderabad-based drug manufacturer reported a marginal dip in its consolidated net profit for the March 2025 quarter. The company posted a profit after tax (PAT) of Rs 903 crore in Q4FY25, slightly lower than Rs 907 crore reported in the same quarter of the previous fiscal. Despite the minor decline in bottom-line performance, Aurobindo's revenue from operations rose to Rs 8,382 crore in the March quarter, up from Rs 7,580 crore in the year-ago period, indicating robust topline growth. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More For the full year ended March 31, 2025, the company delivered a 10% year-on-year increase in PAT at Rs 3,484 crore, compared to Rs 3,169 crore in FY24. Annual revenue also grew significantly to Rs 31,724 crore, up from Rs 29,002 crore the previous year. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. Live Events The drug firm's European operations continue to perform exceptionally well, moving steadily towards the USD 1 billion revenue milestone, Reddy added. Also read: EQT firm Sagility B.V. to offload up to Rs 2,671 crore stake in Sagility India via offer for sale Aurobindo Pharma share price history Over the past year, Aurobindo Pharma's stock has declined by 4.51%. The year-to-date (YTD) performance shows a drop of 12.73%, while the six-month return stands at a negative 4.05%. In contrast, the stock gained 9.06% over the last three months. However, it has slipped 3.16% in the past month. Aurobindo Pharma shares closed 1.4% lower at Rs 1,179.35 on the BSE on Tuesday. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Reuters
27-05-2025
- Business
- Reuters
India's equity benchmarks to open little changed
May 27 (Reuters) - India's benchmark indexes are likely to open little changed on Tuesday, following the previous session's gains on easing trade tensions between the U.S. and the European Union. Gift Nifty futures were trading at 25,027.5 as of 8:08 a.m. IST, indicating that the Nifty 50 (.NSEI), opens new tab will open near its Monday's close of 25,001.15. MSCI Asia ex-Japan (.MIAPJ0000PUS), opens new tab dipped 0.2%, after being largely steady on Monday as U.S. President Donald Trump delayed imposing tariffs on EU goods on June 1, restoring a July 9 deadline. The EU said Trump's decision gave new impetus to trade talks. U.S. markets were closed on Monday for a holiday, while global stock markets climbed. Back home, the early onset of monsoon rains and Reserve Bank of India's record dividend transfer to the government also aided sentiment, although the dividend was below analysts' estimates. Both foreign portfolio investors (FPIs) and domestic institutional investors (DIIs) were buyers on Monday. While DIIs bought shares worth 17.46 billion rupees ($205.2 million), FPIs bought stocks worth $16 million, according to provisional data. ** IndiGo ( opens new tab will be in focus as media report says co-founder Rakesh Gangwal will sell up to a 3.4% stake through a block deal worth nearly $803 million ** FirstCry parent Brainbees Solutions ( opens new tab posts a wider fourth-quarter loss at 767.4 milion rupees even as its revenue rose about 16% ** Aurobindo Pharma ( opens new tab posts flat profit from last year as its margins drop while revenue increases. The pharmaceutical company says it plans for first U.S. Food and Drug Administration submission in FY2026
Yahoo
20-05-2025
- Business
- Yahoo
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
We recently published a list of . In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other Friday's top performers. The stock market finished the trading week in the green territory as investors looked past the series of mixed corporate earnings performance and inflation worries, amid the easing trade tensions between the US and China. The Dow Jones climbed by 0.78 percent, while the S&P 500 and the tech-heavy Nasdaq grew by 0.70 percent and 0.52 percent, respectively. Beyond major indices, 10 companies—predominantly Bitcoin miners and quantum computing firms—registered a strong finish, thanks to fresh corporate developments boosting investor appetite. In this article, we name Friday's 10 top performers and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. Acadia Pharmaceuticals soared by 26.48 percent on Friday to finish at $22.26 apiece after securing the backing of a US District Court concerning a patent infringement case versus Aurobindo Pharma (NSE:ARBN). The case stemmed from a case filed by ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) against Aurobindo for allegedly infringing claims 4 and 5 of US Patent No. 11,452,721. It is alleged that the latter committed patent infringement of its drug Nuplazid. Additionally, the judge said that Aurobindo failed to prove that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) claims were invalid. The ruling marked a significant milestone for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to protect its intellectual property rights. Overall, ACAD ranks 1st on our list of Friday's top performers. While we acknowledge the potential of ACAD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ACAD but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at .
Time of India
19-05-2025
- Business
- Time of India
MF managers shift focus to beaten-down sectors amid April volatility
Healthcare stocks like Dr Reddy's, Cipla, Lupin, and Aurobindo found favour as defensive bets where valuations are reasonable and are considered less affected by geopolitical tensions In April, mutual fund managers adopted a cautious approach to stock purchases. Geopolitical tensions between India and Pakistan, along with US-China trade war uncertainties, influenced their decisions. Fund managers selectively bought stocks in capital goods and power sectors, focusing on those with significant price corrections. Tired of too many ads? Remove Ads Mutual fund managers were cautious while buying stocks in April, keeping in mind the tensions between India and Pakistan, and uncertainty around the outcome of tariff wars as the US and China continued to levy counter tariffs. Fund managers made purchases in segments where stocks have corrected made selective purchases in sectors like capital goods and power, where sharp declines of more than 25% in individual stocks made them good rotational continued to add pharma, given the defensive nature of the industry. Healthcare stocks like Dr Reddy's, Cipla Lupin , and Aurobindo found favour as defensive bets where valuations are reasonable and are considered less affected by geopolitical tensions
